Empagliflozin
Sodium-Glucose Co-Transporter 2 (Sglt2) Inhibitors
Sold as Glyxambi · SYNJARDY · JARDIANCE
- Drug class
- Sodium-Glucose Co-Transporter 2 (Sglt2) Inhibitors
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 4
- Products on record
- 164
- FDA reports (12 mo)
- 8,306
Overview
Empagliflozin is an active pharmaceutical ingredient in the Sodium-Glucose Co-Transporter 2 (Sglt2) Inhibitors group (A10BK). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 151 | May 29, 2026 |
| CA Canada | Health Canada | 8 | August 26, 2025 |
| EU European Union | EMA | 3 | March 30, 2026 |
| US United States | FDA | 2 | January 30, 2026 |
GBUnited Kingdom· MHRA
151 products
Uses
1. Heart failure Empagliflozin is indicated in adults for the treatment of symptomatic chronic heart failure. Chronic kidney disease Empagliflozin is indicated in adults for the treatment of chronic kidney disease.
How to take
CACanada· Health Canada
8 products
Uses
4 Geriatrics 02/2023 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. 2 TABLE OF CONTENTS .............................................................................................................
2 1 INDICATIONS .............................................................................................................. 1 Pediatrics...................................................................................................................
2 Geriatrics ................................................................................................................... 5 2 CONTRAINDICATIONS .................................................................................................
6 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................ 6 4 DOSAGE AND ADMINISTRATION................................................................................. 1 Dosing Considerations ..............................................................................................
EUEuropean Union· EMA
3 products
Uses
1 for available data on combinations studied)
How to take
USUnited States· FDA
2 products
Uses
1 INDICATIONS AND USAGE SYNJARDY SYNJARDY is a combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor and metformin hydrochloride (HCl) immediate-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.
SYNJARDY XR SYNJARDY XR is a combination of empagliflozin, a SGLT2 inhibitor and metformin HCl extended-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus .
Empagliflozin Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of: Cardiovascular (CV) death in adults with established CV disease. ( 1 ) CV death and hospitalization for heart failure in adults with heart failure.
( 1 ) Sustained decline in eGFR, end-stage kidney disease, CV death, and hospitalization in adults with chronic kidney disease at risk of progression. ( 1 ) Limitations of Use : Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus.
Drug interactions
Known interactions involving Empagliflozin. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 328. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL218800356 · revised December 15, 2025
- [2]Health Canada (DPD) · 02443937 · revised August 26, 2025
- [3]European Medicines Agency · EMEA/H/C/003833 · revised March 30, 2026
- [4]FDA DailyMed · 0fdd0255-0055-65… · revised January 30, 2026 [PDF]
- [5]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.